It is well known that therapeutic use of IFN-α is associated with many neuropsychiatric side effects, including depression, anxiety, and cognitive abnormalities (Raison et al., 2005; Hepgul et al., 2016a). The gene discussed is IFNA1; the disease is depressive disorder.